LLY
Lilly’s eczema side quest is looking a lot like a main event
Eli Lilly just dropped Phase 3b data for EBGLYSS — the company’s lebrikizumab therapy — and it didn’t just squeak by. In the ADtouch study, the drug met its primary and secondary endpoints in people with moderate-to-severe hand and foot atopic dermatitis, which is a fancy way of saying: miserable eczema on the parts of your body that make daily life annoying in a thousand tiny ways.
What stood out? The speed. Lilly says more than half of patients reached clear or almost clear skin by Week 16, with improvements showing up as early as one month. It also reported significant itch relief as early as two weeks, plus meaningful pain relief and high patient satisfaction. Dermatology drugs don’t get to be rock stars every day, but this one’s trying.
Why investors should care
This matters because Lilly has been living in the shadow of its obesity blockbuster narrative, but EBGLYSS gives it another shot at turning a specialty asset into a durable revenue stream. A drug that works quickly, reduces symptoms people actually feel, and keeps patients happy is the kind of profile that can help a label expand and keep prescriptions sticky.
The bigger picture
- Fast relief is the whole game in inflammatory skin disease; if patients feel better in weeks, not months, doctors notice.
- Patient satisfaction data is a nice cherry on top because it hints at real-world staying power, not just trial-room optics.
- Big picture: Lilly keeps finding ways to make its pipeline look less like a one-hit wonder and more like a portfolio that can keep printing.